Research Progress on the Relationship Between TRAF6 and Tumor

doi:10.13560/j.cnki.biotech.bull.1985.2016-1137

Abstract

Abstract: Tumor necrosis factor receptor-associated factor 6（TRAF6）is a member of the super TRAF family. It is not only over-expressed in many cancer tissues but also closely associated with tumor cell proliferation,migration,and apoptosis. Studies on relationships between TRAF6 and different types of tumors have emerged recently,and these investigations suggest that interfering or depressing TRAF6 in the role of tumor-related signaling pathways may provide a new therapeutic approach for the treatment of cancers. This review summarizes the correlation between TRAF6 and tumor based on the biological functions of TRAF6 and its critical roles in tumor-related signaling pathways,and explores the significance of TRAF6 in combatting cancers,aiming at providing theoretical basis for the treatment of cancer by targeting TRAF6 in the future.

Key words: tumor necrosis factor receptor-associated factor 6, signaling pathway, tumor

LI Miao, ZHOU Li-jun. Research Progress on the Relationship Between TRAF6 and Tumor[J]. Biotechnology Bulletin, 2017, 33(6): 24-31.

References

[1] Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors（TRAFs）[J]. Oncogene, 2001, 20（44）：6482-6491.
[2] Ha H, Han D, Choi Y. TRAF-mediated TNFR-family signaling[J]. Curr Protoc Immunol, 2009, doi:10.1002/0471142735.im1109ds87.
[3] Yao F, Han Q, Zhong C, et al. TRAF6 promoted the tumorigenicity of esophageal squamous cell carcinoma[J]. Tumor Biology, 2013, 34（5）：3201-3207.
[4] Zhang XL, Dang YW, Li P, et al. Expression of tumor necrosis factor receptor-associated factor 6 in lung cancer tissues[J]. Asian Pac J Cancer Prev, 2014, 15（24）：10591-10596.
[5] Sun H, Li X, Fan L, et al. TRAF6 is upregulated in colon cancer and promotes proliferation of colon cancer cells[J]. Iubmb Life, 2012, 53（9）：775-782.
[6] Rong Y, Wang D, Wu W, et al. TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells[J]. Medical Oncology, 2014, 31（11）：1-10.
[7] Ishida T, Mizushima S, Azuma S, et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region[J]. J Biol Chem, 1996, 271（46）：28745-28748.
[8] Wu H, Arron JR. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology[J]. BioEssays, 2003, 25（11）：1096-1105.
[9] Lamothe B, Campos AD, Webster WK, et al. The RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, lipopolysaccharide, and RANKL[J]. J Biol Chem, 2008, 283 （36）：24871-24880.
[10] Xie P. TRAF molecules in cell signaling and in human diseases[J]. J Mol Signal, 2013, 8（1）：1-31.
[11] Chung JY, Lu M, Yin Q, et al. Structural revelations of TRAF2 function in TNF receptor signaling pathway[J]. Advances in Experimental Medicine and Biology, 2006, 597（4）：93-113.
[12] Hildebrand JM, Luo Z, Manske MK, et al. A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling[J]. J Exp Med, 2011, 207（12）：2569-2579.
[13] Hacker H, Redecke V, Blagoev B, et al. Specificity in toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6[J]. Nature, 2006, 439（7073）：204-207.
[14] Sorrentino A, Thakur N, Grimsby S, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner[J]. Nat Cell Biol, 2008, 10（10）：1199-1207.
[15] Yamashita M, Fatyol K, Jin C, et al. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta[J]. Mol Cell, 2008, 31（6）：918-924.
[16] Sun L, Deng L, Ea CK, et al. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes[J]. Mol Cell, 2004, 14（3）：289-301.
[17] Cohen P. The TLR and IL-1 signalling network at a glance[J]. J Cell Sci, 2014, 127（11）：2383-2390.
[18] Cussonhermance N, Khurana S, Lee TH, et al. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-kB activation but does not contribute to interferon regulatory factor 3 activation[J]. J Biol Chem, 2005, 280（44）：36560-36566.
[19] Kawasaki T, Kawai T. Toll-like receptor signaling pathways[J]. Front Immunol, 2014, 5：461.
[20] Arron JR, Vologodskaia M, Wong BR, et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine（trance）and CD40L-mediated Akt activation[J]. J Biol Chem, 2001, 276（32）：30011-30017.
[21] Neumann D, Lienenklaus S, Rosati O, et al. IL-1beta-induced phosphorylation of PKB/Akt depends on the presence of IRAK-1[J]. Eur J Immunol, 2002, 32（12）：3689-3698.
[22] Wong BR, Besser D, Kim N, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src[J]. Mol Cell, 2000, 4（6）：1041-1049.
[23] Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses[J]. Nat Immunol, 2004, 5（10）：1052-1060.
[24] Trompouki E, Hatzivassiliou E, Tsichritzis T, et al. CYLD is a deu-biquitinating enzyme that negatively regulates NF-kappaB activat-ion by TNFR family members[J]. Nature, 2003, 424（6950）：793-796.
[25] Jin W, Chang M, Paul EM, et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice[J]. J Clin Invest, 2008, 118（5）：1858-1866.
[26] Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes[J]. Science, 2010, 327（5969）：1135-1139.
[27] Yoshida Y, Kumar A, Koyama Y, et al. Interleukin 1 activates STAT3/nuclear factor-kappaB cross-talk via a unique TRAF6- and p65-dependent mechanism[J]. J Biol Chem, 2004, 279（3）：1768-1776.
[28] Wei J, Yuan Y, Jin C, et al. The ubiquitin ligase TRAF6 negatively regulates the JAK-STAT signaling pathway by binding to STAT3 and mediating its ubiquitination[J]. PLoS One, 2012, 7（11）：e49567.
[29] Zhang H, Hu H, Greeley N, et al. STAT3 restrains RANK- and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13[J]. Nat Commun, 2013, 5：5798-5798.
[30] Hindi SM, Paul PK, Saurabh D, et al. Reciprocal interaction between TRAF6 and notch signaling regulates adult myofiber regeneration upon injury[J]. Mol Cell Biol, 2012, 32（23）：4833-4845.
[31] Gudey SK, Sundar R, Mu Y, et al. TRAF6 stimulates the tumor-promoting effects of TGFbeta type I receptor through polyubiquitination and activation of presenilin 1[J]. Sci Signal, 2014, 7（307）：ra2.
[32] 邱文, 单锴, 庞蓉蓉, 等. 大鼠野生型TRAF6基因和TRAF6 shRNA表达质粒的构建及鉴定[J]. 南京医科大学学报：自然科学版, 2011, 31（10）：1407-1411.
[33] Shinohara M, Yun JC, Saji M, et al. Minireview：AKT in thyroid tumorigenesis and progression[J]. Endocrinology, 2007, 148（3）：942-947.
[34] 王敏, 王晓辉, 唐刘君, 等. TRAF6截短体的构建及其对NF-κB信号通路的影响[J]. 安徽医科大学学报, 2011, 46（11）：1113-1116.
[35] Lamothe B, Campos AD, Webster WK, et al. The RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, lipopolysaccharide, and RANKL[J]. J Biol Chem, 2008, 283 （36）：24871-24880.
[36] Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development[J]. Nat Rev Cancer, 2009, 9（8）：537-549.
[37] Heidelberg SB. Tumor Necrosis Factor Receptor-Associated Factor[M]. Berlin Heidelberg：Springer, 2005：1930.
[38] Kashiwada M, Shirakata Y, Inoue JI, et al. Tumor necrosis factor receptor-associated factor 6（TRAF6）stimulates extracellular signal-regulated kinase（ERK）activity in CD40 signaling along a ras-independent pathway[J]. J Exp Med, 1998, 187（2）：237-244.
[39] Perkins ND. NF-κB：tumor promoter or suppressor[J]. Trends Cell Biol, 2004, 14（2）：64-69.
[40] Sun H, Li XB, Meng Y, et al. TRAF6 upregulates expression of HIF-1α and promotes tumor angiogenesis[J]. Cancer Research, 2013, 73（15）：4950-4959.
[41] Feng H, Lopez GY, Kim CK, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis[J]. J Clin Invest, 2014, 124（9）：3741-3756.
[42] Starczynowski DT, Lockwood WW, Deléhouzée S, et al. TRAF6 is an amplified oncogene bridging the RAS and NF-kB pathways in human lung cancer[J]. J Clin Invest, 2011, 121（10）：4095-4105.
[43] 林根, 黄传钟, 苏光建, 等. 下调TRAF6表达对肺癌细胞株恶性生物学行为的影响[J]. 中国肺癌杂志, 2015, 18（11）：661-667.
[44] Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling[J]. Genes Dev, 1999, 13（8）：1015-1024.
[45] Naito A, Azuma S, Tanaka S, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice[J]. Genes to Cells, 1999, 4（6）：353-362.
[46] Kobayashi T, Kim TS, Jacob A, et al. TRAF6 is required for generation of the B-1a B cell compartment as well as T cell-dependent and-independent humoral immune responses[J]. Plos One, 2009, 4（3）：285-289.
[47] Rowland SL, Tremblay MM, Ellison JM, et al. A novel mechanism for TNFR-associated factor 6-dependent CD40 signaling[J]. J Immunol, 2007, 179（7）：4645-4653.
[48] Hostager BS, Haxhinasto SA, Rowland SL, et al. TRAF2-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling[J]. J Biol Chem, 2003, 278（46）：45382-45390.
[49] Ahonen CL, Manning EM, Erickson LD, et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells[J]. Nature Immunology, 2002, 3（5）：451-456.
[50] Jabara H, Laouini D, Tsitsikov E, et al. The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching[J]. Immunity, 2002, 17（3）：265-276.
[51] Liu H, Tamashiro S, Baritaki S, et al. TRAF6 activation in multiple myeloma：a potential therapeutic target[J]. Clinical Lymphoma Myeloma and Leukemia, 2012, 12（12）：155-163.
[52] Chen H, Wu Y, Zhang Y, et al. Hsp70 inhibits lipoplysaccharide-induced NF-Kb activation by interaction with TRAF6 and inhibiting its ubiquitination[J]. Febs Letters, 2006, 580（13）：3145-3152.
[53] Chen H, Li M, Campbell RA, et al. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis[J]. Oncogene, 2006, 25（49）：6520-6527.
[54] Jalukar SV, Hostager BS, Bishop GA. Characterization of the roles of TNF receptor-associated factor 6（TRAF6）in CD40-mediated B lymphocyte effector functions[J]. J Immunol, 2000, 164（2）：623-630.
[55] Yang WL, Wang J, Chan CH, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation[J]. Science, 2009, 325（5944）：1134-1138.
[56] Fukushima T, Matsuzawa S, Kress CL, et al. Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor（TRAF）-mediated inflammatory responses[J]. Proceedings of the National Academy of Sciences, 2007, 104（15）：6371-6376.
[57] Xu G, Wen H, Zhou H, et al. Involvement of IRAKs and TRAFs in anti-beta（2）GPI/beta（2）GPI-induced tissue factor expression in THP-1 cells[J]. Thromb & Haemost, 2011, 106（6）：1158-1169.
[58] Aadams J, Kauffman M. Development of the proteasome inhibitor Velcade（Bortezomib）[J]. Cancer Invest, 2004, 22（2）：304-311.
[59] Kong FC, Zhang JQ, Zeng C, et al. Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6[J]. Journal of Huazhong University of Science & Technology, 2015, 35（3）：343-349.
[60] Liu W, Qi Y, Liu L, et al. Suppression of tumor cell proliferation by quinine via the inhibition of the tumor necrosis factor receptor-associated factor 6-AKT interaction[J]. Mol Med Rep, 2016, 14（3）2171-2179.
[61] Hou J, Wang P, Lin L, et al. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2[J]. J Immunol, 2009, 183（3）：2150-2158.
[62] Hurst DR, Edmonds MD, Scott GK, et al. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis[J]. Cancer Res, 2011, 69（69）：1279-1283.